A detailed history of Black Rock Inc. transactions in Capricor Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 1,628,550 shares of CAPR stock, worth $29.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,628,550
Previous 381,735 326.62%
Holding current value
$29.5 Million
Previous $2.59 Million 199.81%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$4.63 - $7.09 $5.77 Million - $8.84 Million
1,246,815 Added 326.62%
1,628,550 $7.77 Million
Q1 2024

May 10, 2024

BUY
$3.61 - $6.88 $79,643 - $151,786
22,062 Added 6.13%
381,735 $2.59 Million
Q4 2023

Feb 13, 2024

BUY
$2.71 - $5.08 $2,978 - $5,582
1,099 Added 0.31%
359,673 $1.76 Million
Q3 2023

Nov 13, 2023

SELL
$3.42 - $7.85 $179,026 - $410,923
-52,347 Reduced 12.74%
358,574 $1.23 Million
Q2 2023

Aug 11, 2023

BUY
$3.76 - $5.05 $63,698 - $85,552
16,941 Added 4.3%
410,921 $1.96 Million
Q1 2023

May 12, 2023

SELL
$3.78 - $5.03 $169,835 - $225,997
-44,930 Reduced 10.24%
393,980 $1.66 Million
Q4 2022

Feb 13, 2023

BUY
$3.36 - $6.55 $5,651 - $11,017
1,682 Added 0.38%
438,910 $1.69 Million
Q3 2022

Nov 14, 2022

BUY
$3.61 - $6.08 $499,432 - $841,149
138,347 Added 46.29%
437,228 $2.62 Million
Q2 2022

Aug 12, 2022

SELL
$2.89 - $4.51 $10,513 - $16,407
-3,638 Reduced 1.2%
298,881 $1.04 Million
Q1 2022

May 12, 2022

SELL
$2.83 - $5.68 $1,315 - $2,641
-465 Reduced 0.15%
302,519 $1.04 Million
Q4 2021

Feb 10, 2022

BUY
$2.89 - $4.16 $8,042 - $11,577
2,783 Added 0.93%
302,984 $888,000
Q3 2021

Nov 09, 2021

SELL
$3.8 - $5.23 $18,399 - $25,323
-4,842 Reduced 1.59%
300,201 $1.21 Million
Q2 2021

Aug 11, 2021

BUY
$3.16 - $5.72 $963,935 - $1.74 Million
305,043 New
305,043 $1.56 Million

Others Institutions Holding CAPR

About CAPRICOR THERAPEUTICS, INC.


  • Ticker CAPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,346,200
  • Market Cap $440M
  • Description
  • Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for th...
More about CAPR
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.